MedTrace Logo

Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

NCT04108962 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2022-02-01

No results posted yet for this study

Summary

Phase IV, open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis

Conditions

Interventions

DRUG

Fasenra, 30 Mg/mL Subcutaneous Solution

Anti-IL5 receptor alpha monoclonal antibody

Sponsors & Collaborators

  • Baylor Research Institute

    lead OTHER

Principal Investigators

  • Yolanda Mageto, MD · Baylor Scott and White Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-23
Primary Completion
2021-09-24
Completion
2021-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04108962 on ClinicalTrials.gov